TGF-beta Inactivation and TGF-alpha Overexpression Cooperate in an in Vivo Mouse Model to Induce Hepatocellular Carcinoma That Recapitulates Molecular Features of Human Liver Cancer

Overview

Journal Int J Cancer

Specialty Oncology

Date 2009 Dec 19

PMID 20020490

Citations 11

Authors

Ji Yeon Baek

Shelli M Morris

Jean Campbell

Nelson Fausto

Matthew M Yeh

William M Grady

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) results from the cumulative effects of deregulated tumor suppressor genes and oncogenes. The tumor suppressor and oncogenes commonly affected include growth factors, receptors and their downstream signaling pathway components. The overexpression of transforming growth factor alpha (TGF-alpha) and the inhibition of TGF-beta signaling are especially common in human liver cancer. Thus, we assessed whether TGF-alpha overexpression and TGF-beta signaling inactivation cooperate in hepatocarcinogenesis using an in vivo mouse model, MT1/TGFa;AlbCre/Tgfbr2(flx/flx) mice ("TGFa;Tgfbr2(hepko)"), which overexpresses TGF-alpha and lacks a TGF-beta receptor in the liver. TGF-beta signaling inactivation did not alter the frequency or number of cancers in mice with overexpression of TGF-alpha. However, the tumors in the TGFa;Tgfbr2(hepko) mice displayed increased proliferation and increased cdk2, cyclin E and cyclin A expression as well as decreased Cdkn1a/p21 expression compared to normal liver and compared to the cancers arising in the TGF-alpha overexpressing mice with intact TGF-beta receptors. Increased phosphorylated ERK1/2 expression was also present in the tumors from the TGFa;Tgfbr2(hepko) mice and correlated with downregulated Raf kinase inhibitor protein expression, which is a common molecular event in human HCC. Thus, TGF-beta signaling inactivation appears to cooperate with TGF-alpha in vivo to promote the formation of liver cancer that recapitulates molecular features of human HCC.

Citing Articles

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4-TGFα-EGFR signaling.

Wei X, Si A, Zhao S, Fu Y, Li J, Aishanjiang K Cell Mol Biol Lett. 2025; 30(1):15.

PMID: 39885395 PMC: 11781035. DOI: 10.1186/s11658-025-00690-1.

Prognostic Value of TGF-β Expression in Bladder Cancer: A Systematic Review and Meta-analysis.

Kianmehr S, Vahabirad M, Seghatoleslam A, Sadeghi E, Kiani R, Ghasemi H Urol Res Pract. 2024; 50(3):148-153.

PMID: 39495544 PMC: 11562745. DOI: 10.5152/tud.2024.24024.

New and Old Key Players in Liver Cancer.

Cuesta A, Palao N, Bragado P, Gutierrez-Uzquiza A, Herrera B, Sanchez A Int J Mol Sci. 2023; 24(24).

PMID: 38138981 PMC: 10742790. DOI: 10.3390/ijms242417152.

Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases.

Tang Q, Zeng M, Chen L, Fu N Front Pharmacol. 2022; 13:871100.

PMID: 35721201 PMC: 9201453. DOI: 10.3389/fphar.2022.871100.

Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma.

Sivasudhan E, Blake N, Lu Z, Meng J, Rong R Front Cell Dev Biol. 2021; 9:642443.

PMID: 33869193 PMC: 8047153. DOI: 10.3389/fcell.2021.642443.

References

Chytil A, Magnuson M, Wright C, Moses H . Conditional inactivation of the TGF-beta type II receptor using Cre:Lox. Genesis. 2002; 32(2):73-5. DOI: 10.1002/gene.10046. View

Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J . Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer. 2004; 40(10):1485-95. DOI: 10.1016/j.ejca.2004.02.020. View

Bierie B, Moses H . TGF-beta and cancer. Cytokine Growth Factor Rev. 2005; 17(1-2):29-40. DOI: 10.1016/j.cytogfr.2005.09.006. View

Takagi H, Sharp R, Hammermeister C, Goodrow T, Bradley M, Fausto N . Molecular and genetic analysis of liver oncogenesis in transforming growth factor alpha transgenic mice. Cancer Res. 1992; 52(19):5171-7. View

Romero-Gallo J, Sozmen E, Chytil A, Russell W, Whitehead R, Parks W . Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene. 2005; 24(18):3028-41. DOI: 10.1038/sj.onc.1208475. View

Hu Z, Evarts R, Fujio K, Omori N, Omori M, Marsden E . Expression of transforming growth factor alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis. Carcinogenesis. 1996; 17(5):931-8. DOI: 10.1093/carcin/17.5.931. View

Pang R, Poon R . From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007; 72 Suppl 1:30-44. DOI: 10.1159/000111705. View

Keller E, Fu Z, Brennan M . The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem. 2004; 94(2):273-8. DOI: 10.1002/jcb.20169. View

Okano J, Matsumoto K, Nagahara T, Murawaki Y . Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. J Gastroenterol. 2006; 41(2):166-76. DOI: 10.1007/s00535-005-1736-3. View

10.

Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y . Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 2001; 21(1B):657-62. View

11.

Alexandrow M, Moses H . Transforming growth factor beta and cell cycle regulation. Cancer Res. 1995; 55(7):1452-7. View

12.

Yeung K, Janosch P, McFerran B, Rose D, Mischak H, Sedivy J . Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 2000; 20(9):3079-85. PMC: 85596. DOI: 10.1128/MCB.20.9.3079-3085.2000. View

13.

Mishra B, Tang Y, Katuri V, Fleury T, Said A, Rashid A . Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a beta-spectrin, in primary biliary cirrhosis. Liver Int. 2004; 24(6):637-45. DOI: 10.1111/j.1478-3231.2004.0958.x. View

14.

Gordon S, Akopyan G, Garban H, Bonavida B . Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2005; 25(8):1125-42. DOI: 10.1038/sj.onc.1209080. View

15.

Javelaud D, Delmas V, Moller M, Sextius P, Andre J, Menashi S . Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene. 2005; 24(51):7624-9. DOI: 10.1038/sj.onc.1208900. View

16.

Kiss A, Wang N, Xie J, Thorgeirsson S . Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res. 1997; 3(7):1059-66. View

17.

Kretzschmar M, Doody J, Timokhina I, Massague J . A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev. 1999; 13(7):804-16. PMC: 316599. DOI: 10.1101/gad.13.7.804. View

18.

Yeung K, Rose D, Dhillon A, Yaros D, Gustafsson M, Chatterjee D . Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001; 21(21):7207-17. PMC: 99896. DOI: 10.1128/MCB.21.21.7207-7217.2001. View

19.

Hertl M, Cosimi A . Liver transplantation for malignancy. Oncologist. 2005; 10(4):269-81. DOI: 10.1634/theoncologist.10-4-269. View

20.

Schuierer M, Bataille F, Weiss T, Hellerbrand C, Bosserhoff A . Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep. 2006; 16(3):451-6. View